Indomethacin Shortage: What Providers and Prescribers Need to Know in 2026

Indomethacin's supply landscape has grown increasingly fragmented over the past decade. While standard oral capsules remain generally available, recent recalls and manufacturer exits have created real access challenges — particularly for the extended-release formulation, oral suspension, and rectal suppository. This guide provides a clinical overview of the current situation and practical guidance for providers navigating these challenges in 2026.

Current Availability by Formulation

Understanding which indomethacin formulations are currently at risk allows you to proactively adjust prescribing before patients run out.

25 mg and 50 mg immediate-release capsules: Generally available. Multiple generic manufacturers (Glenmark, Lannett, others) continue production. Localized stock-outs are possible but not systematic.

75 mg extended-release capsules: Most at-risk formulation. Affected by Glenmark recall (July 2024, dissolution testing failure) and KVK-Tech recall (May 2025, 9,107 bottles recalled for cGMP deviations). Consider prescribing equivalent IR doses (e.g., 25 mg TID or 50 mg BID) as a contingency.

Oral suspension (25 mg/5 mL): Extremely limited supply; retail price >$1,700/237 mL indicates very few active producers. Consider compounding pharmacy referral for patients requiring liquid formulation.

Rectal suppositories (50 mg): Near-absent from commercial retail channels; retail price data >$8,000/30 suppositories reflects this. Compounding pharmacy may be the only viable route.

IV injection (1 mg): Hospital/neonatal use only. Distributed through hospital pharmacies and drug distributors; subject to separate supply chain dynamics.

Manufacturer Landscape: What Changed

The commercial withdrawal of the Indocin brand (now discontinued in the U.S.) marked the beginning of a long contraction in indomethacin manufacturing. Subsequent exits by Heritage Pharmaceuticals, Mylan, Sandoz, and Teva from specific indomethacin formulations have narrowed the field significantly. The remaining generic manufacturers operate in a market with thin margins, making them vulnerable to quality-based recalls that ripple across the whole supply.

Clinical Alternatives by Indication

The appropriate indomethacin alternative depends heavily on the indication:

Acute Gouty Arthritis

Naproxen: First-line alternative per most guidelines. 500 mg BID for acute gout is widely used and well-tolerated.

Colchicine: Highly effective when given early (within 12-24 hrs). ACR-recommended first-line for patients who cannot tolerate NSAIDs. Dose: 1.2 mg at onset, then 0.6 mg one hour later; low-dose protocol preferred.

Corticosteroids: Oral prednisone 30-40 mg/day tapered over 5-7 days, or intra-articular injection for monoarticular disease. Preferred when NSAIDs and colchicine are both contraindicated.

47,606+ patients found their medications in stock

47K+

Find Indomethacin In Stock Today →

Rheumatoid Arthritis and Osteoarthritis

Meloxicam: Once-daily, preferential COX-2 inhibition, excellent GI profile relative to indomethacin. Generic widely available at $4-10/month.

Celecoxib: Preferred for patients with GI risk factors or history of ulceration. Consider adding PPI when transitioning from indomethacin to celecoxib in high-risk patients.

Ankylosing Spondylitis

NSAIDs are first-line treatment for AS. Indomethacin has been used historically for its potency, but naproxen, diclofenac, and celecoxib are recognized alternatives with comparable efficacy in current evidence. For patients with severe AS who fail two NSAIDs, biologic therapy (TNF inhibitors, IL-17 inhibitors) should be considered per ACR/EULAR guidelines.

Skip the calls, skip the stress.

Find Indomethacin In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Indomethacin-Responsive Headache Syndromes

Hemicrania continua and paroxysmal hemicrania are defined in part by their absolute response to indomethacin. For these diagnoses, there is no validated alternative — the therapeutic trial of indomethacin is both diagnostic and therapeutic. If indomethacin cannot be sourced, consider contacting a compounding pharmacy to prepare custom-dose capsules from indomethacin powder.

Supporting Your Patients

Providers can refer patients to medfinder for providers — a service that calls pharmacies on behalf of your patients to locate their medication. This reduces the burden on your care team and on patients who are dealing with pain while trying to navigate supply issues. Having a provider referral system in place for medications with supply risk is a proactive way to maintain care continuity for your patients.

Prescribing Recommendations for Supply-Risk Patients

For chronic users of 75 mg ER: consider writing a contingency prescription for 25 mg IR TID or 50 mg IR BID

For patients needing liquid formulation: contact compounding pharmacies proactively

For acute gout: have naproxen or colchicine as a back-pocket prescription

For elderly patients: note that indomethacin is on the Beers Criteria — shortage is an opportunity to reassess whether an alternative is clinically preferable